SpyBiotech

SpyBiotech is a clinical stage company utilizing its unique protein superglue technology to develop vaccines against infectious disease and cancer. The company has exclusive rights to apply the SpyTag/SpyCatcher technology to the field of vaccinology. It has announced appointments and clinical trial progress, including the completion of enrollment in Phase I trial of SPYVLP01 targeting Human Cytomegalovirus (HCMV).

SpyBiotech is a clinical stage company utilizing its unique protein superglue technology to develop vaccines against infectious disease and cancer. The company has exclusive rights to apply the SpyTag/SpyCatcher technology to the field of vaccinology. Recent milestones include the completion of enrollment in Phase I trial of SPYVLP01 targeting Human Cytomegalovirus (HCMV), and the appointments of Dr. Prakash Bhuyan as Chief Medical Officer and Keith Dewedoff as Chief Financial Officer.

• Unconfirmed

  SpyBiotech raises $32.5 million in Series A financing[4]SpyBiotech完成3250万美元A轮融资finanznachrichten.de

  Reported: 2021-02-10

  SpyBiotech announced it raised $32.5 million in Series A equity financing. The company said the proceeds will advance clinical development of its vaccine technology platform.

• Unconfirmed

  SpyBiotech appoints Andre Crawford-Brunt to its board[4]SpyBiotech完成3250万美元A轮融资finanznachrichten.de

  Reported: 2021-02-10

  SpyBiotech announced the appointment of Andre Crawford-Brunt, a general partner at Braavos Investment Advisers, to its board.

• Unconfirmed

  SpyBiotech appoints Lutz B. Giebel as chairman[4]SpyBiotech完成3250万美元A轮融资finanznachrichten.de

  Reported: 2021-02-10

  SpyBiotech announced the appointment of Lutz B. Giebel as chairman of its board. The company described the appointment as strengthening governance and oversight as it expands.

1. 1Homepage - SpyBiotechspybiotech.com
2. 2Our Story - SpyBiotechspybiotech.com
3. 3SpyBiotechwikidata.org
4. 4SpyBiotech完成3250万美元A轮融资finanznachrichten.de